(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 1.83% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Amgen's revenue in 2025 is $35,971,000,000.On average, 34 Wall Street analysts forecast AMGN's revenue for 2025 to be $19,586,157,446,283, with the lowest AMGN revenue forecast at $18,497,888,010,192, and the highest AMGN revenue forecast at $20,488,112,570,208. On average, 34 Wall Street analysts forecast AMGN's revenue for 2026 to be $19,947,477,976,524, with the lowest AMGN revenue forecast at $18,331,497,482,853, and the highest AMGN revenue forecast at $21,509,610,403,095.
In 2027, AMGN is forecast to generate $20,491,881,934,905 in revenue, with the lowest revenue forecast at $17,896,943,581,356 and the highest revenue forecast at $23,967,236,185,539.